ReviewAdvances in therapy2019

Rationale for the Early Use of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with Type 2 Diabetes.

Yehuda HandelsmanPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.